Skip to content
Blackberry Empire – Lifestyle
Author:
KODIAK SCIENCES INC.
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
August 6, 2026
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
May 28, 2026
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
May 7, 2026
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
May 1, 2026
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
March 31, 2026
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
March 26, 2026